Merck Serono’s Israel bioincubator fund is a strategic initiative designed to stimulate innovation by bridging the gap between academic research and the biotechnology industry.
Merck Serono is launching the bioincubator program in Israel, one of the world’s top-ranking countries for biomedical research, where it has a longstanding presence. The bioincubator offers both seed financing and access to dedicated, state-of-the-art laboratory facilities within Inter-Lab, Merck Serono’s Israel-based research and development center. Merck Serono is committing a total of EUR 10 million in the bioincubator initiative until 2018.
Israeli start-ups are currently being selected based on their potential for developing innovative technologies aligned with Merck Serono’s strategic focus. By nurturing biotech start-ups at an early stage of development, the company is seeking to secure innovations for future application in its focus business areas of Oncology, Neurodegenerative Diseases, Rheumatology, Fertility and Endocrinology.
More about: